TSWM
CAPR icon

Tyler-Stone Wealth Management’s Capricor Therapeutics CAPR Stock Holding History

Tyler-Stone Wealth Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-90
Closed – – 841
2021
Q4 		$0 Buy
+90
New +$315 ﹤0.01% 916

Other funds holding CAPR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWM
Selective Wealth Management Forest, Virginia $338M AUM 10.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tyler-Stone Wealth Management's CAPR Position: Q1 2022 in Review

Tyler-Stone Wealth Management sold out of Capricor Therapeutics (CAPR) in Q1 2022, closing a stake of 90 shares.

Tyler-Stone Wealth Management first reported a position in CAPR in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 29 funds tracked by Wall St. Rank hold CAPR as of Q1 2022.

  • Tyler-Stone Wealth Management reported no remaining Capricor Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Tyler-Stone Wealth Management sold 90 Capricor Therapeutics shares in Q1 2022.
  • Tyler-Stone Wealth Management first reported a position in Capricor Therapeutics in Q4 2021 and held it in 1 quarter.
  • Tyler-Stone Wealth Management's Capricor Therapeutics position peaked at $0 in Q4 2021.
  • 29 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2022.

Based on Tyler-Stone Wealth Management's 13F filing for Q1 2022, filed 12 May 2022.